Sorrento Therapeutics enters into collaboration with TSRI

Sorrento Therapeutics announced that it has entered into an antibody and vaccine development collaboration with The Scripps Research Institute, or TSRI, of La Jolla, CA. Under the terms of the agreement, Sorrento obtains an exclusive, worldwide license to TSRI's novel technologies based on ghrelin signaling inhibition for the prevention and treatment of obesity and other metabolic disorders.

View Comments (0)